RedHill Biopharma

Sep 19, 2023

FDA Approves Ojjaara for Myelofibrosis; EMA Grants PRIME Designation to Iopofosine I-131; EBGLYSS Receives Positive CHMP Opinion; FDA Accepts Resmetirom NDA; FDA Fast Track Designation to KT-333 for PTCL; RedHill Announces FDA sNDA Approval for Talicia®

Jun 22, 2021

Horizon/ Arrowhead Deal; Dr Reddy’s Lab’s Drug US Launch; Targovax’s ONCOS-102; RedHill’s Oral Opaganib in COVID-19

Jul 06, 2020

Rising Nontuberculous Mycobacterial Infection Prevalence Poses A Major Public Health Concern

Feb 10, 2020

Bridging the gap: Nontuberculous mycobacterium Infections Drug Pipeline

Feb 05, 2020

Nontuberculous Mycobacteria Infection Market: Current status of NTM infection drug discovery and development

Dec 04, 2018

Notizia

Newsletter/Whitepaper